Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Depreciation & Amortization (CF) (2020 - 2025)

Apellis Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $327000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $327000.0 for Q4 2025, down 26.85% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (down 13.3% YoY), and the annual figure for FY2025 was $1.6 million, down 13.3%.
  • Depreciation & Amortization (CF) for Q4 2025 was $327000.0 at Apellis Pharmaceuticals, down from $339000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for APLS hit a ceiling of $476000.0 in Q4 2023 and a floor of $282000.0 in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $423000.0 (2023), compared with a mean of $403500.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 365.26% in 2021 and later decreased 26.85% in 2025.
  • Apellis Pharmaceuticals' Depreciation & Amortization (CF) stood at $373000.0 in 2021, then increased by 4.02% to $388000.0 in 2022, then increased by 22.68% to $476000.0 in 2023, then fell by 6.09% to $447000.0 in 2024, then fell by 26.85% to $327000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $327000.0 (Q4 2025), $339000.0 (Q3 2025), and $446000.0 (Q2 2025) per Business Quant data.